Treat and Inform Your Patients With Confidence

colon cancer

Myriad Oncology can provide you and your patients with information about their colon cancer that will provide you both peace of mind. About 1 in 10 colon cancers are caused by an inherited mutation1 and knowing this information about your patient will help guide treatment and risk management decisions, as well as provide information on familial risk.

Patient care starts with knowledge and your patients deserve accurate and actionable hereditary cancer test results that you trust.

Myriad Oncology's Tests for Colon Cancer and What Answers They Provide:​

Hereditary cancer testing

myRisk genetic testing

The Myriad myRisk® test is a 35-gene cancer panel that will provide your patients with colon cancer information on:

  • Whether their colon cancer is hereditary (or caused by a genetic mutation) – Up to 10% of all colorectal cancers are caused by an inherited gene mutation.1
  • Their risk of developing additional cancers – Patients with a mutation in Lynch syndrome genes face up to a 30% risk of developing cancer at another site within 10 years and a 50% risk within 15 years.2 This includes ovarian, prostate, endometrial, and pancreatic cancer.
  • Potential surgical considerations and treatment eligibility – A patient’s genetic status can help guide treatment and risk management decisions. 
  • Potential hereditary cancer risk for family members – Knowing mutation status provides the opportunity for family members to take proactive screening and/or preventative measures if appropriate. 

By incorporating leading medical society guidelines into the results through our myRisk Medical Management Tool, myRisk can provide comprehensive information about your patient’s unique cancer. Using industry leading accuracy, unmatched turnaround time, and a lifetime commitment to patients, myRisk should be a part of colon cancer workups. 

explore other cancer types

Click the cancer type below to see what test(s) and answers Myriad Oncology offers for that cancer type.

  1. Yurgelun M, et al. Prevalence of germline cancer susceptibility gene mutations in a clinic-based series of colorectal cancer patients. Presented at ASCO 2016 Jun 7.
  2. Weissman SM, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome — a review. J Genet Couns. 2011 Feb;20(1):5-19.

Website Feedback